Published in Rheumatology (Oxford) on January 10, 2006
Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol (2009) 5.91
Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1β activation and severe autoinflammation in mice. Immunity (2011) 2.69
Familial Mediterranean fever with a single MEFV mutation: where is the second hit? Arthritis Rheum (2009) 2.02
As a new inflammatory marker for familial Mediterranean fever: neutrophil-to-lymphocyte ratio. Inflammation (2013) 1.83
Chronic inflammation in FMF: markers, risk factors, outcomes and therapy. Nat Rev Rheumatol (2010) 1.45
The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation. Nat Immunol (2017) 1.38
Is neutrophil/lymphocyte ratio associated with subclinical inflammation and amyloidosis in patients with familial Mediterranean fever? Biomed Res Int (2013) 1.28
Profile of blood cells and inflammatory mediators in periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) syndrome. BMC Pediatr (2010) 1.09
Hereditary auto-inflammatory disorders and biologics. Springer Semin Immunopathol (2006) 1.06
Pathogenetic mechanisms of amyloid A amyloidosis. Proc Natl Acad Sci U S A (2013) 1.01
Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat Immunol (2016) 0.99
High prevalence of spondyloarthritis and ankylosing spondylitis among familial Mediterranean fever patients and their first-degree relatives: further evidence for the connection. Arthritis Res Ther (2013) 0.97
Evaluation of intima media thickness of the common and internal carotid arteries with inflammatory markers in familial Mediterranean fever as possible predictors for atherosclerosis. Rheumatol Int (2008) 0.96
Renal amyloidosis in children. Pediatr Nephrol (2011) 0.96
Familial Mediterranean fever: current perspectives. J Inflamm Res (2016) 0.95
Systemic arthritis in children: a review of clinical presentation and treatment. Int J Inflam (2011) 0.94
Coexistence of vasculitides with familial Mediterranean fever. Rheumatol Int (2011) 0.91
Developments in the scientific and clinical understanding of autoinflammatory disorders. Arthritis Res Ther (2009) 0.91
Mediterranean Fever gene analysis in the azeri turk population with familial mediterranean Fever: evidence for new mutations associated with disease. Cell J (2013) 0.88
Familial mediterranean Fever as an emerging clinical model of atherogenesis associated with low-grade inflammation. Open Cardiovasc Med J (2010) 0.87
Familial mediterranean Fever: a retrospective clinical and molecular study in the East of anatolia region of Turkey. Open Rheumatol J (2010) 0.87
Clinical immunology review series: An approach to the patient with a periodic fever syndrome. Clin Exp Immunol (2011) 0.86
Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens. Arthritis Res Ther (2013) 0.86
The myths we believed in familial Mediterranean fever: what have we learned in the past years? Semin Immunopathol (2015) 0.85
The expanded clinical profile and the efficacy of colchicine therapy in Egyptian children suffering from familial Mediterranean fever: a descriptive study. Ital J Pediatr (2012) 0.85
Early ultrasonographic markers of atherosclerosis in patients with familial Mediterranean fever. Clin Rheumatol (2007) 0.84
Monogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes: finding the right balance in response to danger signals. Clin Immunol (2010) 0.84
MEFV gene mutations and its impact on the clinical course in ulcerative colitis patients. Rheumatol Int (2010) 0.83
[Periodic fever syndrome/autoinflammatory syndrome]. Z Rheumatol (2009) 0.82
Pneumonia in a patient with familial Mediterranean fever successfully treated with anakinra--case report and review. Rheumatol Int (2010) 0.81
Left ventricular diastolic function evaluated with tissue Doppler imaging in children with familial Mediterranean fever. Clin Rheumatol (2008) 0.81
What is the best acute phase reactant for familial Mediterranean fever follow-up and its role in the prediction of complications? A systematic review. Rheumatol Int (2015) 0.81
The rate and significance of Mediterranean fever gene mutations in patients with ankylosing spondylitis: a three-month, longitudinal clinical study. Rheumatol Int (2008) 0.80
The evaluation of carotid intima-media thickness in children with familial Mediterranean fever. Clin Rheumatol (2007) 0.80
TLR polymorphisms in FMF: association of TLR-2 (Arg753Gln) and TLR-4 (Asp299Gly, Thre399Ile) polymorphisms and myeloid cell TLR-2 and TLR-4 expression with the development of secondary amyloidosis in FMF. Inflammation (2011) 0.80
Vascular comorbidities in familial Mediterranean fever. Rheumatol Int (2011) 0.80
The risk of familial Mediterranean fever in MEFV heterozygotes: a statistical approach. PLoS One (2013) 0.79
Can serum fetuin-A be regarded as an inflammatory marker among patients with familial Mediterranean fever? Dig Dis Sci (2013) 0.78
Plasminogen activator inhibitor-1 gene polymorphism in Iranian Azeri Turkish patients with FMF disease and its association with amyloidosis. Eur J Pediatr (2012) 0.78
Neutrophil-lymphocyte ratio in children with familial Mediterranean fever: Original article. Eur J Rheumatol (2015) 0.78
Discontinuing colchicine in symptomatic carriers for MEFV (Mediterranean FeVer) variants. Clin Rheumatol (2016) 0.78
The "other" vasculitis syndromes and kidney involvement. Pediatr Nephrol (2009) 0.77
Long-term kinetics of AA amyloidosis and effects of inflammatory restimulation after disappearance of amyloid depositions in mice. Clin Exp Immunol (2015) 0.77
A novel insertion mutation identified in exon 10 of the MEFV gene associated with Familial Mediterranean Fever. BMC Med Genet (2014) 0.77
Concurrent systemic AA amyloidosis can discriminate primary sclerosing cholangitis from IgG4-associated cholangitis. World J Gastroenterol (2012) 0.77
Relationship between periodontal destruction and gene mutations in patients with familial Mediterranean fever. Clin Rheumatol (2015) 0.76
Comparison of the efficacy of once- and twice-daily colchicine dosage in pediatric patients with familial Mediterranean fever - a randomized controlled noninferiority trial. Arthritis Res Ther (2016) 0.76
Mean Platelet Volume and Splenomegaly as Useful Markers of Subclinical Activity in Egyptian Children with Familial Mediterranean Fever: A Cross-Sectional Study. Int J Chronic Dis (2015) 0.76
MEFV gene mutations in Turkish children with juvenile idiopathic arthritis. Eur J Pediatr (2013) 0.76
Association of familial Mediterranean fever in Turkish children with inflammatory bowel disease. Turk Pediatri Ars (2014) 0.75
P wave dispersion and QT dispersion in adult Turkish migrants with familial mediterranean fever living in Germany. Int J Med Sci (2014) 0.75
The presence of MEFV gene mutations in patients with primary osteoarthritis who require surgery. Korean J Intern Med (2013) 0.75
Evaluation of the Mean Platelet Volume and Red Cell Distribution Width in FMF: Are They Related to Subclinical Inflammation or Not? Int J Chronic Dis (2014) 0.75
Killer Cell Immunoglobulin-Like Receptor (KIR) Genotype Distribution in Familial Mediterranean Fever (FMF) Patients. Med Sci Monit (2015) 0.75
Review of autoinflammatory diseases, with a special focus on periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome. Acta Paediatr (2016) 0.75
Serum Amyloid A Level in Egyptian Children with Familial Mediterranean Fever. Int J Rheumatol (2016) 0.75
[Role of genetics in familial Mediterranean fever]. Z Rheumatol (2017) 0.75
Relation of fragmented QRS to tissue Doppler-derived parametersin patients with familial Mediterranean fever. Wien Klin Wochenschr (2015) 0.75
Down-regulation of adiponectin in patients with familial Mediterranean fever during attack-free period. Rheumatol Int (2011) 0.75
Familial Mediterranean fever, review of the literature. Clin Rheumatol (2017) 0.75
[Heterozygote forms of familial Mediterranean fever can be manifested in adults as myofacial pain syndrome]. Z Rheumatol (2015) 0.75
Frequency of familial Mediterranean fever (MEFV) gene mutations in patients with biopsy-proven primary glomerulonephritis. Clin Rheumatol (2017) 0.75
Evaluation of endothelial dysfunction in patients with familial Mediterranean fever: the relationship between the levels of asymmetric dimethylarginine and endocan with carotid intima-media thickness and endothelium-dependent vasodilation. Clin Rheumatol (2017) 0.75
Changes in Cerebral Blood Flow in Patients with Familial Mediterranean Fever. Noro Psikiyatr Ars (2016) 0.75
New insights into the epigenetics of inflammatory rheumatic diseases. Nat Rev Rheumatol (2017) 0.75
Risk factors for subclinical inflammation in children with Familial Mediterranean fever. Rheumatol Int (2015) 0.75
The effect of colchicine and disease severity on physical growth in children with familial Mediterranean fever. Clin Rheumatol (2015) 0.75
The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med (1994) 8.10
Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ (2000) 6.10
Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature (1997) 5.47
Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood (1998) 4.07
Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med (1999) 3.88
Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest (1993) 2.92
Human lysozyme gene mutations cause hereditary systemic amyloidosis. Nature (1993) 2.78
Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature (2002) 2.71
Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet (2001) 2.71
Amyloidosis and the respiratory tract. Thorax (1999) 2.36
Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum (1997) 2.31
Long-term survival in systemic amyloid A amyloidosis complicating Crohn's disease. Gastroenterology (1997) 2.18
Bone scintigraphy as clue to previous torture. Lancet (1991) 2.16
Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet (1993) 2.00
Risk factors for coronary heart disease and acute-phase proteins. A population-based study. Eur Heart J (1999) 1.87
C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation (2001) 1.81
Prevalence and significance of the familial Mediterranean fever gene mutation encoding pyrin Q148. QJM (2001) 1.80
A novel variant of transthyretin, 59Thr-->Lys, associated with autosomal dominant cardiac amyloidosis in an Italian family. Circulation (1995) 1.77
Pentameric and decameric structures in solution of serum amyloid P component by X-ray and neutron scattering and molecular modelling analyses. J Mol Biol (1997) 1.77
Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-I. Kidney Int (1998) 1.71
Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. Br J Haematol (2000) 1.66
Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford) (2005) 1.65
Preprocedural inflammatory markers do not predict restenosis after successful coronary stenting. Am Heart J (2004) 1.59
Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat Med (1997) 1.56
Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen. Proc Natl Acad Sci U S A (2000) 1.47
Curative hepatorenal transplantation in systemic amyloidosis caused by the Glu526Val fibrinogen alpha-chain variant in an English family. QJM (2000) 1.45
Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy. Rheumatology (Oxford) (2003) 1.43
Imaging of haemodialysis-associated amyloidosis with 123I-serum amyloid P component. Lancet (1991) 1.42
An autosomal dominant periodic fever associated with AA amyloidosis in a north Indian family maps to distal chromosome 1q. Arthritis Rheum (2000) 1.41
Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation (1998) 1.36
Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc Natl Acad Sci U S A (1994) 1.35
Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis. Proc Natl Acad Sci U S A (1992) 1.35
Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. Transplantation (1998) 1.35
Acute phase response and evolution of familial Mediterranean fever. Lancet (1999) 1.34
Rapid automated enzyme immunoassay of serum amyloid A. Clin Chem (1994) 1.31
The genetic basis of autosomal dominant familial Mediterranean fever. QJM (2000) 1.29
Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart (2011) 1.28
Primary localised amyloidosis of the orbit. Br J Ophthalmol (1996) 1.28
Takayasu's arteritis in Turkey - clinical and angiographic features of 248 patients. Clin Exp Rheumatol (2009) 1.25
Imaging amyloidosis with radiolabelled SAP. Eur J Nucl Med (1995) 1.24
Rapid automated high sensitivity enzyme immunoassay of C-reactive protein. Clin Chem (1998) 1.22
SAA1 alleles as risk factors in reactive systemic AA amyloidosis. Amyloid (1998) 1.20
Hearing improvement in a patient with variant Muckle-Wells syndrome in response to interleukin 1 receptor antagonism. Ann Rheum Dis (2006) 1.17
Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis (2011) 1.15
Amyloidosis: a review of recent diagnostic and therapeutic developments. Br J Haematol (1997) 1.14
Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris. Am J Cardiol (1998) 1.14
Phenotypic and molecular analysis of six human cell lines derived from patients with plasma cell dyscrasia. Br J Haematol (1999) 1.13
Treatment of amyloidosis. Am J Kidney Dis (1995) 1.11
The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo. J Clin Invest (1994) 1.11
The first international standard for serum amyloid A protein (SAA). Evaluation in an international collaborative study. J Immunol Methods (1998) 1.10
Evidence for an excess of B→D*τ(-)ν(τ) decays. Phys Rev Lett (2012) 1.10
A new apolipoprotein Al variant, Trp50Arg, causes hereditary amyloidosis. QJM (1995) 1.09
Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis. Genes Immun (2004) 1.09
Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene. J Clin Invest (1996) 1.09
Amyloidosis and the lung. Chron Respir Dis (2006) 1.09
Observation of time-reversal violation in the B0 meson system. Phys Rev Lett (2012) 1.09
Familial nephropathic systemic amyloidosis caused by apolipoprotein AI variant Arg26. Q J Med (1994) 1.06
Binding of pentraxins to different nuclear structures: C-reactive protein binds to small nuclear ribonucleoprotein particles, serum amyloid P component binds to chromatin and nucleoli. Clin Exp Immunol (1994) 1.05
C-reactive protein and bacterial infection in preterm infants. Eur J Pediatr (1990) 1.05
Transthyretin gene analysis in European patients with suspected familial amyloid polyneuropathy. Brain (1995) 1.04
Amyloid and the gut. Dig Dis (1997) 1.03
Molecular and functional characterisation of E2F-5, a new member of the E2F family. Oncogene (1995) 1.02
Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis. Brain (1999) 1.02
Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. Circulation (1996) 1.02
Heart transplantation for homozygous familial transthyretin (TTR) V122I cardiac amyloidosis. Am J Transplant (2008) 1.00
The liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patients. Gut (1998) 1.00
Hereditary renal amyloidosis associated with variant lysozyme in a large English family. Nephrol Dial Transplant (1999) 0.99
Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation. Eur J Nucl Med (1998) 0.98
Unicentric Castleman's disease complicated by systemic AA amyloidosis: a curable disease. QJM (2002) 0.98
Monitoring the acute phase response to vaso-occlusive crisis in sickle cell disease. J Clin Pathol (1994) 0.98
The phosphorylation state of the retinoblastoma (RB) protein in G0/G1 is dependent on growth status. Oncogene (1991) 0.97
Proto-oncogenic properties of the DP family of proteins. Oncogene (1995) 0.97
Pyrin/marenostrin mutations in familial Mediterranean fever. QJM (1998) 0.96